Apocept (asunercept) / Apogenix 
Welcome,         Profile    Billing    Logout  
 16 Diseases   2 Trials   2 Trials   70 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Apocept (asunercept) / Apogenix
2021-006005-30: Asunercept for the treatment of patients with moderate to severe COVID-19 disease Asunercept para el tratamiento de pacientes con enfermedad por COVID-19 moderada a severa

Not yet recruiting
3
640
Europe
Asunercept, APG101, Concentrate for solution for infusion
Apogenix AG, Apogenix AG, Federal Republic of Germany, represented by the Federal Ministry of Education and Research, Federal Republic of Germany, represented by the Federal Ministry of Education and Research
Moderate to Severe COVID-19 Disease Enfermedad por COVID-19 de moderada a severa, Moderate to Severe COVID-19 Disease Enfermedad por COVID-19 de moderada a severa, Diseases [C] - Virus Diseases [C02]
 
 
ASUCOV, NCT05639192: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Terminated
3
34
Europe, RoW
Asunercept, Placebo
Apogenix GmbH
COVID-19
08/23
08/23
ACOVACT, NCT04351724 / 2020-001302-30: Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

Recruiting
2/3
500
Europe
Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care, Rivaroxaban, Thromboprophylaxis, Candesartan, non-RAS blocking antihypertensives, Remdesivir, Asunercept 400mg, Asunercept 100mg, Asunercept 25mg, Pentaglobin
Medical University of Vienna, Kaiser Franz Josef Hospital, SMZ-Ost Donauspital, Otto Wagner Hospital, Hospital Hietzing, Wilhelminenspital Vienna, Medical University Innsbruck, Medical University of Graz, Kepler University Hospital
COVID-19
12/21
03/22
NCT05447195: Phase 2 Study of CAN008 in Subjects With GBM

Recruiting
2
117
RoW
CAN008, APG101, Placebo
CANbridge Life Sciences Ltd.
Newly-diagnosed Glioblastoma
01/24
08/24
NOA-20, NCT03158389 / 2015-002752-27: NCT Neuro Master Match - N²M²

Completed
1/2
228
Europe
APG101, Alectinib, Alecensa, Idasanutlin, Atezolizumab, Vismodegib, Erivedge, Temsirolimus, Troisel, Palbociclib, Ibrance
University Hospital Heidelberg, German Cancer Aid, German Cancer Research Center, National Center for Tumor Diseases, Heidelberg
Glioblastoma, Adult
02/23
02/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Apocept (asunercept) / Apogenix
2021-006005-30: Asunercept for the treatment of patients with moderate to severe COVID-19 disease Asunercept para el tratamiento de pacientes con enfermedad por COVID-19 moderada a severa

Not yet recruiting
3
640
Europe
Asunercept, APG101, Concentrate for solution for infusion
Apogenix AG, Apogenix AG, Federal Republic of Germany, represented by the Federal Ministry of Education and Research, Federal Republic of Germany, represented by the Federal Ministry of Education and Research
Moderate to Severe COVID-19 Disease Enfermedad por COVID-19 de moderada a severa, Moderate to Severe COVID-19 Disease Enfermedad por COVID-19 de moderada a severa, Diseases [C] - Virus Diseases [C02]
 
 
ASUCOV, NCT05639192: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

Terminated
3
34
Europe, RoW
Asunercept, Placebo
Apogenix GmbH
COVID-19
08/23
08/23
ACOVACT, NCT04351724 / 2020-001302-30: Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

Recruiting
2/3
500
Europe
Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care, Rivaroxaban, Thromboprophylaxis, Candesartan, non-RAS blocking antihypertensives, Remdesivir, Asunercept 400mg, Asunercept 100mg, Asunercept 25mg, Pentaglobin
Medical University of Vienna, Kaiser Franz Josef Hospital, SMZ-Ost Donauspital, Otto Wagner Hospital, Hospital Hietzing, Wilhelminenspital Vienna, Medical University Innsbruck, Medical University of Graz, Kepler University Hospital
COVID-19
12/21
03/22
NCT05447195: Phase 2 Study of CAN008 in Subjects With GBM

Recruiting
2
117
RoW
CAN008, APG101, Placebo
CANbridge Life Sciences Ltd.
Newly-diagnosed Glioblastoma
01/24
08/24
NOA-20, NCT03158389 / 2015-002752-27: NCT Neuro Master Match - N²M²

Completed
1/2
228
Europe
APG101, Alectinib, Alecensa, Idasanutlin, Atezolizumab, Vismodegib, Erivedge, Temsirolimus, Troisel, Palbociclib, Ibrance
University Hospital Heidelberg, German Cancer Aid, German Cancer Research Center, National Center for Tumor Diseases, Heidelberg
Glioblastoma, Adult
02/23
02/23

Download Options